Vertex Pharmaceuticals VRTX financials

Healthcare & Pharma · Statements and segments from its SEC filings, 2008 to 2025.

Vertex Pharmaceuticals revenue, gross and operating margin, net income, free cash flow, cash and debt by quarter and by fiscal year, and revenue by segment, read from the company's own filings with the US Securities and Exchange Commission. Free to everyone; the Risk & Quality report that scores the company is the paid step.

revenue by product: Trikafta/Kaftrio, Other product revenues, Symdeko/Symkevi, Alyftrek, Other revenues, Casgevy, Other / unallocated
revenue by region: United States, Europe, Other

The numbers

Annual figures

Line	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$1.7B	$2.5B	$3B	$4.2B	$6.2B	$7.6B	$8.9B	$9.9B	$11B	$12B
Gross profit	$1.5B*	$2.2B*	$2.6B*	$3.6B*	$5.5B*	$6.7B*	$7.9B*	$8.6B*	$9.5B*	$10.4B*
Operating income	$9.9M	$123.2M	$635.2M	$1.2B	$2.9B	$2.8B	$4.3B	$3.8B	-$232.9M	$4.2B
Net income	-$112.1M	$263.5M	$2.1B	$1.2B	$2.7B	$2.3B	$3.3B	$3.6B	-$535.6M	$4B
EPS (diluted)	-$0.46	$1.04	$8.09	$4.51	$10.29	$9.01	$12.82	$13.89	-$2.08	$15.32
Operating cash flow	$236.1M	$844.9M	$1.3B	$1.6B	$3.3B	$2.6B	$4.1B	$3.5B	-$492.6M	$3.6B
Free cash flow	$179.5M*	$745.5M*	$1.2B*	$1.5B*	$3B*	$2.4B*	$3.9B*	$3.3B*	-$790.3M*	$3.2B*
Cash & equivalents	$1.2B	$1.7B	$2.7B	$3.1B	$6B	$6.8B	$10.5B	$10.4B	$4.6B	$5.1B
Gross margin	87.6%	88.9%	86.6%	86.8%	88.1%	88.1%	87.9%	87.2%	86.1%	86.2%
Operating margin	0.6%	5.0%	20.8%	28.8%	46.0%	36.7%	48.2%	38.8%	-2.1%	34.8%
Net margin	-6.6%	10.6%	68.8%	28.3%	43.7%	30.9%	37.2%	36.7%	-4.9%	32.9%

Latest quarters

Line	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$2.8B	$2.9B*	$2.8B	$3B	$3.1B	$3.2B*	$3B	$3.3B
Gross profit	$2.4B*	$2.5B*	$2.4B*	$2.6B*	$2.7B*	$2.7B*	$2.6B*	$2.8B*
Operating income	$1.1B	$1B*	$630.1M	$1.2B	$1.2B	$1.2B*	$1.1B	$1.2B
Net income	$1B	$913M*	$646.3M	$1B	$1.1B	$1.2B*	$1B	$1.1B
EPS (diluted)	$4.01	$3.53*	$2.49	$3.99	$4.20	$4.64*	$4.02	$4.31
Operating cash flow	$1.4B*	$584.6M*	$818.9M	$1.1B*	$1.2B*	$498M*	$1.4B	$1.1B*
Free cash flow	$1.3B*	$492M*	$778.2M*	$927.4M*	$1.1B*	$348.6M*	$1.3B*	$1B*
Cash & equivalents	$5.2B	$4.6B	$4.7B	$5B	$4.9B	$5.1B	$5.5B	$6.1B
Gross margin	85.8%	85.5%	86.9%	86.3%	86.5%	85.4%	86.8%	85.3%
Operating margin	40.3%	35.2%	22.7%	38.8%	38.6%	37.8%	38.1%	37.4%
Net margin	37.7%	31.4%	23.3%	34.8%	35.2%	37.3%	34.5%	33.0%

Revenue by product

Line	FY2020	FY2021*	FY2022*	FY2023	FY2024	FY2025*
Trikafta/Kaftrio	$3.9B	$5.7B	$7.7B	$8.9B	$10.2B	$10.3B
Other product revenues	-	-	-	$924.5M	$781.5M	$820.1M
Symdeko/Symkevi	$628.6M	$420.4M	$180M	-	-	-
Alyftrek	-	-	-	$0	$0	-
Other revenues	$2.9M	$1M	$0	$0	-	-
Other / unallocated	-	$1.5B*	$1.1B*	-	-	$868.5M*

Not all revenue is allocated to a segment; the parts add up to less than the total.

Revenue by region

Line	FY2023	FY2024	FY2025
United States	$6B	$6.7B	$7.5B
Europe	$3.1B	$3.5B	$3.5B
Other	$719.8M	$881.3M	$992.4M

* derived: a fourth quarter as the year less the three filed quarters, or a remainder as the total less the parts. All other figures are as filed.

About this page

Every figure on this page is read from Vertex Pharmaceuticals's own SEC filings: the statement lines from the SEC's XBRL company-facts feed, the revenue splits from the segment and revenue notes of each 10-K and 10-Q. Nothing is typed in or estimated. The cache refreshes daily.

Read the Risk & Quality report on Vertex Pharmaceuticals or see all companies.